Clinical Trial Update: Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052) [Phase 3]

View source ↗

Summary

This Phase 3 trial update evaluates the efficacy, immunogenicity, and safety of the V503 vaccine in Chinese males with papillomavirus infections; the study is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Papillomavirus Infections

Drugs mentioned

• V503

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Papillomavirus Infections | Phase 3 | Status: ACTIVE_NOT_RECRUITING